Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
A data analysis from the Physicians Advocacy Institute and Avalere Health found corporate buyouts are leaving patients in low-population areas with fewer options, as doctors are opting to go elsewhere.
Many if not most hospitals and other provider organizations take a decided interest in what their peer institutions are doing with AI. A major motivator for the keen curiosity is gauging how well one is keeping up with the Joneses. So to speak.
The FTC has back-burnered its price collusion case against CVS Caremark, Optum Rx and Express Scripts after significant staff departures at the agency left it uncertain how to proceed.
Questions remain about the alleged breach on a legacy server at Oracle Health, as the nature of the attacks and scope of stolen data are still being investigated.
Liberator Medical Supply was accused of offering doctors kickbacks, such as discounted and free supplies, in exchange for filling prescriptions with its products.
The last count submitted to HHS in October pegged the number at 100 million. Now that figure sits at 190 million, and the company continues its investigation.
The Centers for Medicare & Medicaid Services appealed a court ruling that ordered the agency to change the star rating for UnitedHealthcare's Medicare Part D plans, which had been reduced due to a disputed phone call. CMS has now dropped the appeal.
When Larry Ellison talks about healthcare AI, people invest. At least, that’s what happened after the Oracle chairman enthused over AI’s potential to cook up vaccines for cancer.
Tim Noel is taking the reins of the insurance giant in the aftermath of the murder of its previous CEO, Brian Thompson. Noel has been with the company since 2007.
The agency found 82 cases of anaphylaxis associated with glatiramer acetate, sold under the brand names Copaxone and Glatopa, including 19 that emerged after patients had been taking these drugs for more than a year.